Enovis Co. (NYSE:ENOV) Stock Position Lifted by Royce & Associates LP

Royce & Associates LP lifted its holdings in shares of Enovis Co. (NYSE:ENOV) by 16.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,403,685 shares of the company’s stock after acquiring an additional 346,317 shares during the quarter. Enovis makes up 0.9% of Royce & Associates LP’s portfolio, making the stock its 3rd biggest position. Royce & Associates LP owned 4.30% of Enovis worth $103,479,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Ridgewood Investments LLC purchased a new position in shares of Enovis during the 2nd quarter valued at about $44,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Enovis in the 3rd quarter worth about $55,000. Innealta Capital LLC purchased a new stake in Enovis during the second quarter valued at approximately $65,000. Benjamin F. Edwards & Company Inc. raised its holdings in Enovis by 28.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock valued at $76,000 after buying an additional 371 shares during the period. Finally, Heritage Family Offices LLP bought a new stake in shares of Enovis in the 3rd quarter worth about $206,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ENOV. Evercore ISI lowered their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research note on Tuesday, October 1st. JMP Securities started coverage on Enovis in a research note on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price for the company. JPMorgan Chase & Co. cut their price target on Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Finally, Needham & Company LLC reissued a “buy” rating and set a $65.00 price target on shares of Enovis in a report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Enovis Stock Down 1.9 %

Shares of ENOV opened at $45.59 on Friday. Enovis Co. has a 52 week low of $38.27 and a 52 week high of $65.03. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The business’s fifty day moving average price is $42.33 and its two-hundred day moving average price is $45.33.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.11. The company had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.56 earnings per share. As a group, equities analysts forecast that Enovis Co. will post 2.79 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.